

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

1.-29. (cancelled)

30. (new) A hemocompatible surface consisting of:

a material located on or in the hemocompatible surface, wherein the material consists of an artificial compound, a natural organic compound, or an inorganic compound, or a mixture thereof; and,

a constituent of an outer layer of a blood cell, a constituent of an outer layer of a mesothelial cell or a combination thereof,

wherein the hemocompatible surface does not comprise thrombodulin and the hemocompatible surface does not comprise whole, intact cells.

31. (new) The hemocompatible surface of claim 30, wherein the hemocompatible surface consists of a natural organic compound and a constituent of an outer layer of a blood cell, a constituent of an outer layer of a mesothelial cell or a combination thereof,

the hemocompatible surface consisting of a surface extracted from an animal organ, an animal organ part, a vascular system, or a combination thereof.

32. (new) The hemocompatible surface of claim 30, wherein the constituent consists of:

an oligosaccharide;

a polysaccharide;

lipid portions of a glycoprotein, lipid portions of a glycolipid, or lipid portions of a proteoglycan; or

combinations thereof;

wherein the constituent is obtained from outer layers of blood cells, outer layers of mesothelial cells, or combinations thereof.

33. (new) The hemocompatible surface of claim 30, wherein the constituent consists of heparin sulfate obtained from erythrocyte plasma membranes of animals or humans.

34. (new) The hemocompatible surface of claim 30, wherein the constituent consists of an oligosaccharide or a polysaccharide portion of a proteoglycan, wherein the proteoglycan is hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparin sulfate, or keratin sulfate, or a mixture thereof.

35. (new) The hemocompatible surface of claim 30, wherein the constituent consists of glycoporphins, glycosphingolipids, or combinations thereof.

36. (new) The hemocompatible surface of claim 30, wherein the hemocompatible surface is non-thrombogenic, non-immunogenic or a combination thereof.

37. (new) The hemocompatible surface of claim 30, wherein the material consists of a high-molecular weight organic compound, a metal, a metal oxide, an alloy, a ceramic, a glass, a mineral, or a mixture thereof.

38. (new) An article, device, or material comprising the hemocompatible surface of claim 30.

39. (new) A hemocompatible surface comprising:

a material located on or in the hemocompatible surface, wherein the material comprises an artificial compound, a natural organic compound, or an inorganic compound, or a mixture thereof; and,

a non-thrombogenic constituent of an outer layer of a blood cell, a non-thrombogenic constituent of an outer layer of a mesothelial cell or a combination thereof, the non-thrombogenic constituent separated and isolated from at least one of blood cells and mesothelial cells, the non-thrombogenic constituent consisting of an oligosaccharide; a polysaccharide; lipid portions of a glycoprotein, lipid portions of a glycolipid, or lipid portions of a proteoglycan; or combinations thereof,

wherein the hemocompatible surface does not comprise entire cells.

40. (new) The hemocompatible surface of claim 39, wherein the hemocompatible surface comprises a natural organic compound and a non-thrombogenic constituent of an outer layer of a blood cell, a constituent of an outer layer of a mesothelial cell or a combination thereof,

the hemocompatible surface comprises a surface extracted from an animal organ, an animal organ part, a vascular system, or a combination thereof.

41. (new) The hemocompatible surface of claim 39, wherein the non-thrombogenic constituent consists of heparin sulfate obtained from erythrocyte plasma membranes of animals or humans.

42. (new) The hemocompatible surface of claim 39, wherein the non-thrombogenic constituent consists of an oligosaccharide or a polysaccharide portion of a proteoglycan, wherein the proteoglycan is hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparin sulfate, or keratin sulfate, or a mixture thereof.

43. (new) The hemocompatible surface of claim 39, wherein the non-thrombogenic constituent consists of glycoproteins, glycosphingolipids, or combinations thereof.

44. (new) The hemocompatible surface of claim 39, wherein the hemocompatible surface is non-immunogenic.

45. (new) The hemocompatible surface of claim 39, wherein the material comprises a high-molecular weight organic compound, a metal, a metal oxide, an alloy, a ceramic, a glass, a mineral, or a mixture thereof.

46. (new) An article, device, or material comprising the hemocompatible surface of claim 39.

47. (new) A hemocompatible surface consisting of:

- / a material located on or in the hemocompatible surface, wherein the material consists of an artificial compound, a natural organic compound, or an inorganic compound, or a mixture thereof; and,

- a non-thrombogenic constituent of an outer layer of a blood cell, a non-thrombogenic constituent of an outer layer of a mesothelial cell or a combination thereof, the non-thrombogenic constituent separated and isolated from at least one of blood cells and mesothelial cells,

- wherein the hemocompatible surface does not consist of entire cells.

48. (new) The hemocompatible surface of claim 47, wherein the hemocompatible surface consists of a natural organic compound and a non-thrombogenic constituent of an outer layer of a blood cell, a non-thrombogenic constituent of an outer layer of a mesothelial cell or a combination thereof,

the hemocompatible surface consisting of a surface extracted from an animal organ, an animal organ part, a vascular system, or a combination thereof.

49. (new) The hemocompatible surface of claim 47, wherein the non-thrombogenic constituent consists of:

- an oligosaccharide;
- a polysaccharide;
- lipid portions of a glycoprotein, lipid portions of a glycolipid, or lipid portions of a proteoglycan; or
- combinations thereof;

wherein the non-thrombogenic constituent is obtained from outer layers of blood cells, outer layers of mesothelial cells, or combinations thereof.